34^th European Diabetes Congress

Endocrine and Diabetes Biomarkers

A biomarker is any substance, structure, or process that should be measurable in the body or its products and it also influences or predicts the incidence of outcome or disease. For predicting type 1 diabetes, a biomarker should be present in a subset of the population, and this subset should have an influence on the proportion of people in whom this type 1 diabetes develops. A biomarker should also present a significant risk for the development of type 1 diabetes within a defined period of time or diagnose a “stage” in the progression to clinical or symptomatic type1 diabetes. As described in this article, most of the biomarkers are  used for the prediction of type 1 diabetes are islet-specific supporting the concept that, before overt hyperglycaemia, type 1 diabetes is generally predominantly a targeted disease rather than a systemic disease.

Atomic Biomarkers can be separated as a trademark that is precisely measured and gaged as a pointer of typical natural methods, pathogenic methodology, or pharmacologic reactions to a pharmaceutical intercession.

Biomarkers have fundamental influences in driving clinical trials and treating the patients. Progress in sub-atomic diagnostics helps medicinal experts make proficient, experimentally legitimate choices. All the more efficient disclosure and use of biomarkers in the development of ant diabetes medications will rely on upon quickening our comprehension of the pathogenesis of diabetes and particularly its macro vascular entanglements. Procedural upgrades in different fields, particularly tumour, are started to demonstrate the way towards the better models of diabetes pathogenesis and atomic biomarker revelation.